Zynex — Investor Presentation (April 2010)
19 slides from Zynex's investor presentation, Apr 20, 2010
Slide 1: Zynex, Inc. (OTCBB: ZYXI) April 2010
EE Z fi E ”) Zynex, Inc. (OTCBB: ZYXI) April 2010
Slide 2: Forward Looking Statements
EE ZYNEX Forward Looking Statements The following includes financial estimates and forward-looking statements. These estimates are based on present circumstances, information currently available, and assumptions about future revenues, industry growth, and general economic conditions. Estimates are i
Slide 3: Zynex Overview
ee ZYNEXD Zynex Overview m Develops, manufactures, and markets non-invasive FDA- and _ European Union-cleared electrotherapy medical devices for pain relief/management as well as stroke and spinal cord rehabilitation a US markets for Zynex’ products are estimated at $500 million; addressable interna
Slide 4: History
SS YKIEXY ZYNEX History 1996 Founded by Thomas Sandgaard with his own capital as a wholesaler of TENS electrotherapy pain management devices 1999 First Zynex-manufactured device cleared by FDA 2001 Shifted from wholesale-only to direct sales to physicians/end-users and billing insurance carriers 200
Slide 5: Products
2 Products m Products are FDA and European Union cleared, obtained by prescription only, designed for home use, and usually covered by medical insurance a Proprietary devices used to augment healing and reduce acute/chronic pain as well as assist in recovery for stroke and spinal cord injuries (SCI)
Slide 6: Product Matrix
. Product Matrix Z NEX Zynex Applications Market Typical Payor Products Growth Truwave Pain Relief 5% Medicare, Private ValuTENS Insurance, Work Comp., Retail Interferential IFe000 Pain relief, post-op orthopedic 5% Medicare, Private iF8100 surgery, edema reduction, Insurance, Work increase circulat
Slide 7: Business Model
2 Business Model ZYNEX Development/ Manufacturin: = Contract manufacturer ' Distribution faclty in Colorado 1 Ships devices to sales reps in field | Doctor/Thera 1 Sales rep stocks cinic 1 Doctor issues patient a script Sales Reps 1 Distrbute inventory t patients or phystians * fst pale inte stun an
Slide 8: Customer Reach
[ [ a Customer Reach m 26 US. States and 8 Foreign Countries
Slide 9: Business Drivers
ZYNEXD Business Drivers m Sales reps’ relationships with physicians/hospitals drive scripts/orders Device is purchased or “rented” per physicians prescription Industry consolidation provides attractive opportunities to add reps m Customer Service and Billing/Claims centers (back-office) are an essen
Slide 10: Competitive Advantages
ee YKIEXD ZYNEX Competitive Advantages m 60-day guaranteed product coverage Guarantee of coverage by the company and use of product for 60 days removes barrier to entry/trial for a patient and physician Patient has the option of purchasing device at retail or returning it where it can be re-used aft
Slide 11: Growth Opportunities
A YKIEXY ZYNEX Growth Opportunities m Further penetrate the highly-profitable, established domestic market in traditional electrotherapy Zynex currently has only an estimated 4% market share with two primary competitors Continue to hire experienced full-time sales reps with established relationships
Slide 12: Competitive Landscape
SS Competitive Landscape Revenues/Patients Serviced Products ZYNEX Sales & Marketing Zynex 2009 net revenues of §18.7mm (68% growth over 2008). 90k scripts written for its products. Electrotherapy and NeuroMove. High- end hybrid products ~30 full and 70 part-time sales reps in the US, Limited intern
Slide 13: Management Profile
SS Management Profile ZYNEX = Thomas Sandgaard, CEO Nr, Sandyaard has a degree in electronics enginsering fom the Odense Tekmum and an MBA fromm the, Copenhagen Business School, Prior to founding the Company, Mr. Sandgaard held management positions with ITT, Siemens, GN Danavax, Dataco and Bhlps Tel
Slide 14: Corporate Information
eee YKIEXY ZYNEX Corporate Information a Common Stock: 30,497,318 shares outstanding as of Mar. 24, 2010 a Warrants: 153,148 outstanding as of March 31, 2010 a Thomas Sandgaard owns 18.2mm shares representing roughly 60% of the outstanding Common Stock = Auditors: GHP Horwath, PC = Corporate Counsel
Slide 15: Historical Trends
A YNIEXD i ZYNEX Historical Trends 20000 5 18000 + 160005 14000 5 12000 5 Revenues ('000s) 2009 Financial Metrics ('000: BNetincome =CF Ops Sales 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr 45
Slide 16: Income Statement
ZYNEX Income Statement ZXNEX, INC. AND SUBSIDIARY ‘CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) ‘Thuee Months Ended Yeu Ended December 3 December’, 2m0e 2. 2p ne Netreverme: Rental 3 27335m { 2pmj18 $ Isms $ 79RD; Sales 2g740s 1045516 s14ges 3825,205 ProvilerSettlewent Gee Note! E i i
Slide 17: Balance Sheet
SS Balance Sheet ZNNEX, INC AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS ZYNEX Decenber 31, Deceniber 31, ASSETS 2000 208 Cash 22,5 E Accounts receivable, net 5,089023 5,614,996 Inventory 2,083,790 2,200 €00 Prepaid expenses 139,405 Bm4 Defined taxasset 364,000 648,000 Other cunent assets 16
Slide 18: Outlook
2 YKIEXD , ZYNEX, Outlook = Continued growth of sales reps and back-end support services to support forecasted top-line growth a Net earnings growth a Positive cash flow from operations = Completion and build-out of new headquarters/distribution facility 418
Slide 19: Summary
. ZYNEXD Summary m Products are FDA and European Union cleared, obtained by prescription only, and commonly covered by medical insurance = $500 million addressable US existing market for existing products and similar sized market internationally m 70%+ gross profit margin m Cash flow positive and GA